Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming?

References

• Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571–573.
   Google Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19:108–119.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3–8.
   PubMed Web of Science ®Google Scholar
• Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356–3364.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Greenberg PD, Hingorani SR. Molecular pathways: myeloid complicity in cancer. Clin Cancer Res. 2014;20:5157–5170.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739–752.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–268.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008;68:2561–2563.
   PubMed Web of Science ®Google Scholar
• Tang F, Barbacioru C, Wang Y, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6:377–382.
   PubMed Web of Science ®Google Scholar
• Shalek AK, Benson M. Single-cell analyses to tailor treatments. Sci Transl Med. 2017;9:eaan4730.
   PubMed Web of Science ®Google Scholar
• Giladi A, Amit I. Single-cell genomics: a stepping stone for future immunology discoveries. Cell. 2018;172:14–21.
   PubMed Web of Science ®Google Scholar
• Shalek AK, Satija R, Adiconis X, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature. 2013;498:236–240.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay PK, Gierahn TM, Roederer M, et al. Single-cell technologies for monitoring immune systems. Nat Immunol. 2014;15:128–135.
   PubMed Web of Science ®Google Scholar
• Waks AG, Saltzman A, Choudhury AD, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.
   PubMed Web of Science ®Google Scholar
• Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4:650–661.
   PubMed Web of Science ®Google Scholar
• Quandt D, Zucht HD, Amann A, et al. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget. 2017;8:48507–48520.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–548.
   PubMed Web of Science ®Google Scholar
• Sumanasuriya S, Lambros M, de Bono J. Application of liquid biopsies in cancer targeted therapy. Clin Pharmacol Ther. 2017;102:745–747.
   PubMed Web of Science ®Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9:eaan2415.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–1659.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164–1177.
   PubMed Web of Science ®Google Scholar
• Murugaesu N, Wilson GA, Birkbak NJ, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 2015;5:821–831.
   PubMed Web of Science ®Google Scholar
• Bhang HC, Ruddy DA, Krishnamurthy Radhakrishna V, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015;21:440–448.
   PubMed Web of Science ®Google Scholar
• Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6:254ra125.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–892.
   PubMed Web of Science ®Google Scholar
• Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72:4875–4882.
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63:247–257.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9:e87705.
   PubMed Web of Science ®Google Scholar
• Coaña YP, Wolodarski M, Poschke I, et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8:21539–21553.
   PubMedGoogle Scholar
• Coaña YP, Poschke I, Gentilcore G, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production. Cancer Immunol Res. 2013;1:158–162.
   PubMed Web of Science ®Google Scholar
• Quail D, Joyce J. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437.
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–5596.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Bronte V, Brunet LR, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunotherapy Cancer. 2017;5:44.
   PubMed Web of Science ®Google Scholar
• Kumar V, Patel S, Tcyganov E, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208–220.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174.
   PubMed Web of Science ®Google Scholar
• Schouppe E, De Baetselier P, Van Ginderachter JA, et al. Instruction of myeloid cells by the tumor microenvironment: open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology. 2012;1:1135–1145.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425–426.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Comms. 2016;7:12150.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553–1560.
   PubMed Web of Science ®Google Scholar
• Okła K, Wertel I, Polak G, et al. Tumor-associated macrophages and myeloid-derived suppressor cells as immunosuppressive mechanism in ovarian cancer patients: progress and challenges. Int Rev Immunol. 2016;35:372–385.
   PubMed Web of Science ®Google Scholar
• Marini O, Spina C, Mimiola E, et al. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016;7:27676–27688.
   PubMedGoogle Scholar
• Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254–1261.
   PubMed Web of Science ®Google Scholar
• Elliott LA, Doherty GA, Sheahan K, et al. Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol. 2017;8:86.
   PubMed Web of Science ®Google Scholar
• Brandau S, Moses K, Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol. 2013;23:171–182.
   PubMed Web of Science ®Google Scholar
• Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61:1155–1167.
   PubMed Web of Science ®Google Scholar
• Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, et al. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012;35:107–115.
   PubMed Web of Science ®Google Scholar
• Condamine T, Dominguez GA, Youn JI, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1:aaf8943.
   PubMed Web of Science ®Google Scholar
• Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12:191–200.
   PubMed Web of Science ®Google Scholar
• Damuzzo V, Pinton L, Desantis G, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom. 2014;88:77–91.
   PubMed Web of Science ®Google Scholar
• Duffy A, Zhao F, Haile L, et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother. 2013;62:299–307.
   PubMed Web of Science ®Google Scholar
• Heuvers ME, Muskens F, Bezemer K, et al. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer. 2013;81:468–474.
   PubMed Web of Science ®Google Scholar
• Idorn M, Køllgaard T, Kongsted P, et al. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63:1177–1187.
   PubMed Web of Science ®Google Scholar
• Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17:21–29.
   PubMed Web of Science ®Google Scholar
• Davis MM. A prescription for human immunology. Immunity. 2008;29:835–838.
   PubMed Web of Science ®Google Scholar
• SPIDIA. Germany: SPIDIA; [cited 2017 Dec 11]. Available from: www.spidia.eu
   Google Scholar
• CANCER-ID. [cited 2017 Dec 11]. Available from: www.cancer-id
   Google Scholar
• Chattopadhyay PK, Roederer M. A mine is a terrible thing to waste: high content, single cell technologies for comprehensive immune analysis. Am J Transplant. 2015;15:1155–1161.
   PubMed Web of Science ®Google Scholar
• Fay ME, Myers DR, Kumar A, et al. Cellular softening mediates leukocyte demargination and trafficking, thereby increasing clinical blood counts. Proc Natl Acad Sci USA. 2016;113:1987–1992.
   PubMed Web of Science ®Google Scholar
• Lyons YA, Wu SY, Overwijk WW, et al. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017;1:26.
   PubMed Web of Science ®Google Scholar
• Horowitz A, Strauss-Albee DM, Leipold M, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013;5:208ra145.
   PubMed Web of Science ®Google Scholar
• Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol. 2002;20:155–162.
   PubMed Web of Science ®Google Scholar
• Seah YFS, Hu H, Merten CA. Microfluidic single-cell technology in immunology and antibody screening. Mol Aspects Med. 2018;59:47–61.
   PubMed Web of Science ®Google Scholar
• Shi Q, Qin L, Wei W, et al. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci USA. 2012;109:419–424.
   PubMed Web of Science ®Google Scholar
• Ma C, Fan R, Ahmad H, et al. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011;17:738–743.
   PubMed Web of Science ®Google Scholar
• MAQC Consortium. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28:827–838.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57–63.
   PubMed Web of Science ®Google Scholar
• Chung W, Eum HH, Lee HO, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Comms. 2017;8:15081.
   PubMed Web of Science ®Google Scholar
• Villani A-C, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356:eaah4573.
   PubMed Web of Science ®Google Scholar
• Rozenblatt-Rosen O, Stubbington MJT, Regev A, et al. The human cell atlas: from vision to reality. Nature. 2017;550:451–453.
   PubMed Web of Science ®Google Scholar
• Cao Z, Chen C, He B, et al. A microfluidic device for epigenomic profiling using 100 cells. Nat Methods. 2015;12:959–962.
   PubMed Web of Science ®Google Scholar
• Blueprint Epigenome. [cited 2017 Nov 18]. Available from: http://www.blueprint-epigenome.eu
   Google Scholar
• Stunnenberg HG, International Human Epigenome Consortium, Hirst M. The international human epigenome consortium: a blueprint for scientific collaboration and discovery. Cell. 2016;167:1145–1149.
   PubMed Web of Science ®Google Scholar
• Medaglia C, Giladi A, Stoler-Barak L, et al. Spatial reconstruction of immune niches by combining photoactivatable reporters and scRNA-seq. Science. 2017;358:1622–1626.
   PubMed Web of Science ®Google Scholar
• Stoeckius M, Hafemeister C, Stephenson W, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14:865–868.
   PubMed Web of Science ®Google Scholar
• Chen L, Ge B, Casale FP, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell. 2016;167:1398–1414.
   PubMed Web of Science ®Google Scholar
• Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016;4:3.
   PubMed Web of Science ®Google Scholar
• Mias GI, Yusufaly T, Roushangar R, et al. MathIOmica: an integrative platform for dynamic omics. Sci Rep. 2016;6:37237.
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures. [cited 2017 Nov 28]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
   Google Scholar
• Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530.
   PubMed Web of Science ®Google Scholar
• Scannell JW, Bosley J. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One. 2016;11:e0147215.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375:1289–1294.
   PubMed Web of Science ®Google Scholar
• Human Cell Atlas. [cited 2017 Nov 28]. Available from: https://www.humancellatlas.org
   Google Scholar
• Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31:214–234.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262.
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169:750–765.
   PubMed Web of Science ®Google Scholar
• Cui TX, Kryczek I, Zhao L, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39:611–621.
   PubMed Web of Science ®Google Scholar
• Farsaci B, Donahue RN, Grenga I, et al. Analyses of pre-therapy peripheral immunoscore and response to vaccine therapy. Cancer Immunol Res. 2016;4:755–765.
   PubMed Web of Science ®Google Scholar
• Yang G, Shen W, Zhang Y, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8:38378–38388.
   PubMedGoogle Scholar
• Angell TE, Lechner MG, Smith AM, et al. Circulating myeloid-derived suppressor cells predict differentiated thyroid cancer diagnosis and extent. Thyroid. 2016;26:381–389.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang Z, Wu L, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 2013;8:e57114.
   PubMed Web of Science ®Google Scholar
• Arihara F, Mizukoshi E, Kitahara M, et al. Increase in CD14 + HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62:1421–1430.
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang B, Wang B, et al. Increased CD14 + HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013;62:1439–1451.
   PubMed Web of Science ®Google Scholar
• Sun HL, Zhou X, Xue YF, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol. 2012;18:3303–3309.
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60:1419–1430.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.
   PubMed Web of Science ®Google Scholar
• Jordan KR, Amaria RN, Ramirez O, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62:1711–1722.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma X, Zhu C, et al. The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis. PLoS One. 2016;11:e0164514.
   PubMed Web of Science ®Google Scholar
• Tada K, Kitano S, Shoji H, et al. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunol Res. 2016;4:592–599.
   PubMed Web of Science ®Google Scholar
• Li X, Xing YF, Lei AH, et al. Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value for hepatocellular carcinoma patients. Oncotarget. 2017;8:24380–24388.
   PubMedGoogle Scholar
• Wu C, Wu X, Zhang X, et al. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. Int J Clin Exp Med. 2015;8:15173–15181.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang L, Wang H, et al. Tumor-induced CD14 + HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immunother. 2015;64:389–399.
   PubMed Web of Science ®Google Scholar
• Kitano S, Postow MA, Ziegler CGK, et al. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res. 2014;2:812–821.
   PubMed Web of Science ®Google Scholar
• Verma C, Eremin JM, Robins A, et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal Treg profile with treatment and correlation of Treg levels with pathological response to NAC. J Transl Med. 2013;11:16.
   PubMed Web of Science ®Google Scholar
• Giallongo C, Parrinello NL, La Cava P, et al. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. J Cell Mol Med. 2018;22:1070–1080.
   PubMed Web of Science ®Google Scholar
• Kanterman J, Sade-Feldman M, Biton M, et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014;74:6022–6035.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Yamashita T, Arai K, et al. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 2016;65:715–725.
   PubMed Web of Science ®Google Scholar
• Feng PH, Lee KY, Chang YL, et al. CD14 + S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non–small cell lung Cancer. Am J Respir Crit Care Med. 2012;186:1025–1036.
   PubMed Web of Science ®Google Scholar
• Liu CY, Wang YM, Wang CL, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:35–45.
   PubMed Web of Science ®Google Scholar
• Wang L, Chang EWY, Wong SC, et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190:794–804.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Zhao F, Lee S, et al. Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697). Clin Cancer Res. 2017;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 Vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res. 2013;6:18–26.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Kanterman J, Klieger Y, et al. Clinical significance of circulating CD33 + CD11b + HLA-DR- myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res. 2016;22:5661–5672.
   PubMed Web of Science ®Google Scholar
• Martens A, Wistuba-Hamprecht K, Foppen MG, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22:2908–2918.
   PubMed Web of Science ®Google Scholar
• Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4:345–353.
   PubMed Web of Science ®Google Scholar
• Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer. 2013;133:1653–1663.
   PubMed Web of Science ®Google Scholar
• Chevalier MF, Trabanelli S, Racle J, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127:2916–2929.
   PubMed Web of Science ®Google Scholar
• Schneider T, Sevko A, Heussel CP, et al. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin Exp Immunol. 2015;180:467–474.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Brooks TR, Duggan MC, et al. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother. 2015;64:149–159.
   PubMed Web of Science ®Google Scholar
• Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm. 2015;2015:159269.
   PubMed Web of Science ®Google Scholar
• Shipp C, Speigl L, Janssen N, et al. A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. Cell Mol Life Sci. 2016;73:4043–4061.
   PubMed Web of Science ®Google Scholar
• Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1:10.
   PubMedGoogle Scholar
• Waldron TJ, Quatromoni JG, Karakasheva TA, et al. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology. 2013;2:e24117.
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Lubbers J, Nijman HW, et al. Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology. 2015;4:e954829. eCollection 2015 Jan.
   PubMed Web of Science ®Google Scholar
• Pyzer AR, Stroopinsky D, Rajabi H, et al. MUC1 mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129:1791–1801.
   PubMed Web of Science ®Google Scholar
• Liu YF, Chen YY, He YY, et al. Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia. J Leukoc Biol. 2017;102:449–458.
   PubMed Web of Science ®Google Scholar
• Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120:457–471.
   PubMed Web of Science ®Google Scholar
• Waight JD, Netherby C, Hensen ML, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. 2013;123:4464–4478.
   PubMed Web of Science ®Google Scholar
• Solito S, Falisi E, Diaz-Montero CM, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118:2254–2265.
   PubMed Web of Science ®Google Scholar
• Choi J, Suh B, Ahn YO, et al. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumor Biol. 2012;33:121–129.
   PubMedGoogle Scholar
• Bailur JK, Gueckel B, Derhovanessian E, et al. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res. 2015;17:34.
   PubMed Web of Science ®Google Scholar
• Gonda K, Shibata M, Ohtake T, et al. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 2017;14:1766–1774.
   PubMed Web of Science ®Google Scholar
• Jin G, Zhang Y, Chang X, et al. Increased percentage of mo-MDSCs in human peripheral blood may be a potential indicator in the diagnosis of breast cancer. Oncol Res Treat. 2017;40:603–608.
   PubMed Web of Science ®Google Scholar
• Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783–3797.
   PubMed Web of Science ®Google Scholar
• Yuan XK, Zhao XK, Xia YC, et al. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res. 2011;39:1381–1391.
   PubMed Web of Science ®Google Scholar
• Eruslanov E, Neuberger M, Daurkin I, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012;130:1109–1119.
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Diaz-Montero CM, Rayman PA, et al. Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI). J Clin Oncol. 2017;35:e16005.
   Web of Science ®Google Scholar
• Liu J, Zhou Y, Huang Q, et al. CD14 + HLA-DRlow/− expression: a novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett. 2015;9:1167–1172.
   PubMed Web of Science ®Google Scholar
• Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14 + HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750–760.
   PubMed Web of Science ®Google Scholar
• Christiansson L, Söderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS One. 2013;8:e55818.
   PubMed Web of Science ®Google Scholar
• Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60:1269–1279.
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562–6568.
   PubMed Web of Science ®Google Scholar
• Zhao F, Hoechst B, Duffy A, et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology. 2012;136:176–183.
   PubMed Web of Science ®Google Scholar
• Brusa D, Simone M, Gontero P, et al. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int J Urol. 2013;20:971–978.
   PubMed Web of Science ®Google Scholar
• OuYang LY, Wu XJ, Ye SB, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med. 2015;13:47.
   PubMed Web of Science ®Google Scholar
• Toor SM, Syed Khaja AS, El Salhat H, et al. Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients. Front Immunol. 2016;7:560.
   PubMed Web of Science ®Google Scholar
• Toor SM, Elkord E. Comparison of myeloid cells in circulation and in the tumor microenvironment of patients with colorectal and breast cancers. I Immunol Res. 2017;2017:7989020.
   PubMedGoogle Scholar
• Chen HM, Ma G, Gildener-Leapman N, et al. Myeloid derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy. Clin Cancer Res. 2015;21:4073–4085.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang G, Li G, et al. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. Tumour Biol. 2015;36:7987–7996.
   PubMed Web of Science ®Google Scholar
• Jiao ZJ, Gao JJ, Hua SH, et al. Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. World J Gastroenterol. 2012;18:5454–5461.
   PubMed Web of Science ®Google Scholar
• Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol. 2015;74:390–400.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncol. 2011;13:591–599.
   PubMed Web of Science ®Google Scholar
• Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncol. 2010;12:351–365.
   PubMed Web of Science ®Google Scholar
• Gielen PR, Schulte BM, Kers-Rebel ED, et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuonc. 2016;18:1253–1264.
   Google Scholar
• Dubinski D, Wölfer J, Hasselblatt M, et al. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol. 2016;18:807–818.
   PubMed Web of Science ®Google Scholar
• Shoji H, Tada K, Kitano S, et al. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget. 2017;8:95083–95094.
   PubMedGoogle Scholar
• Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135:234–243.
   PubMed Web of Science ®Google Scholar
• Wang D, An G, Xie S, et al. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumor Biol. 2016;37:10427–10433.
   PubMedGoogle Scholar
• Kalathil S, Lugade AA, Miller A, et al. Higher frequencies of GARP + CTLA-4+ Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T cell functionality. Cancer Res. 2013;73:2435–2444.
   PubMed Web of Science ®Google Scholar
• Shen P, Wang A, He M, et al. Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res. 2014;44:639–650.
   PubMed Web of Science ®Google Scholar
• Iwata T, Kondo Y, Kimura O, et al. PD-L1 + MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep. 2016;6:39296.
   PubMed Web of Science ®Google Scholar
• Gao XH, Tian L, Wu J, et al. Circulating CD14 + HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 2017;47:1061–1071.
   PubMed Web of Science ®Google Scholar
• Romano A, Parrinello NL, Vetro C, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015;168:689–700.
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor induced myeloid-derived suppressor cells. J Immunol. 2009;182:5693–5701.
   PubMed Web of Science ®Google Scholar
• Lathers DMR, Clark JI, Achille NJ, et al. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004;53:422–430.
   PubMed Web of Science ®Google Scholar
• Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123:1580–1589.
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Sakakura K, Toyoda M, et al. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci. 2012;103:976–983.
   PubMed Web of Science ®Google Scholar
• Trellakis S, Bruderek K, Hütte J, et al. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 2013;19:328–336.
   PubMed Web of Science ®Google Scholar
• Califano JA, Khan Z, Noonan KA, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:30–38.
   PubMed Web of Science ®Google Scholar
• Weed DT, Vella JL, Reis IM, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:39–48.
   PubMed Web of Science ®Google Scholar
• Chen WC, Lai CH, Chuang HC, et al. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. Head Neck. 2017;39:347–355.
   PubMed Web of Science ®Google Scholar
• Chen Y, Pan G, Tian D, et al. Functional analysis of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in patients with lung squamous cell carcinoma. Oncol Lett. 2017;14:349–354.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015;21:5453–5459.
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546–2553.
   PubMed Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70:4335–4345.
   PubMed Web of Science ®Google Scholar
• Chevolet I, Speeckaert R, Schreuer M, et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015;13:9.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gebhardt C, Umansky L, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136:2352–2360.
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res. 2014;20:1601–1609.
   PubMed Web of Science ®Google Scholar
• Rudolph BM, Loquai C, Gerwe A, et al. Increased frequencies of CD11b + CD33 + CD14 + HLA-DRlow myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol. 2014;23:202–204.
   PubMed Web of Science ®Google Scholar
• Görgün GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121:2975–2987.
   PubMed Web of Science ®Google Scholar
• Ramachandran I, Martner A, Pisklakova A, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013;190:3815–3823.
   PubMed Web of Science ®Google Scholar
• Gowda M, Godder K, Kmieciak M, et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med. 2011;9:170.
   PubMed Web of Science ®Google Scholar
• Du J, Sun X, Song Y. The study of CD14 + HLA-DR-/low myeloid-derived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function. Cell Mol Biol (Noisy-Le-Grand). 2017;63:62–67.
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Bosch JJ, Thompson JA, et al. Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008;57:1493–1504.
   PubMed Web of Science ®Google Scholar
• Vetsika EK, Koinis F, Gioulbasani M, et al. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014;2014:659294.
   PubMed Web of Science ®Google Scholar
• Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62:909–918.
   PubMed Web of Science ®Google Scholar
• Wu L, Deng Z, Peng Y, et al. Ascites-derived IL-6 and IL-10 synergistically expand CD14 + HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 2017;8:76843–76856.
   PubMedGoogle Scholar
• Sanford DE, Porembka MR, Panni RZ, et al. A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. J Cancer Ther. 2013;4:797–803.
   PubMedGoogle Scholar
• Annels NE, Shaw VE, Gabitass RF, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother. 2013;63:175–183.
   PubMed Web of Science ®Google Scholar
• Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61:1373–1385.
   PubMed Web of Science ®Google Scholar
• Vuk-Pavlovic S, Bulur PA, Lin Y, et al. Immunosuppressive CD14 + HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010;70:443–455.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Stam AG, Lougheed SM, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31.
   PubMedGoogle Scholar
• Hossain DMS, Pal SK, Moreira DF, et al. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res. 2015;21:3771–3782.
   PubMed Web of Science ®Google Scholar
• Chi N, Tan Z, Ma K, et al. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med. 2014;7:3181–3192.
   PubMed Web of Science ®Google Scholar
• Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299–9307.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270–8278.
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15:2148–2157.
   PubMed Web of Science ®Google Scholar
• Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044–3048.
   PubMed Web of Science ®Google Scholar
• Najjar YG, Rayman PA, Jia X, et al. Myeloid derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL-1β, IL-8, CXCL5 and Mip-1α. Clin Cancer Res. 2017;23:2346–2355.
   PubMed Web of Science ®Google Scholar
• Flörcken A, Takvorian A, Singh A, et al. Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Immunol Lett. 2015;168:260–267.
   PubMed Web of Science ®Google Scholar